Zobrazeno 1 - 10
of 11
pro vyhledávání: '"621"'
Publikováno v:
Diabetes. 70
Objective: The incidence of hyperglycemia in patients receiving enteral nutrition ranges from 34.5-50% and is associated with increased morbidity and mortality. This study examined glycemic control in hospitalized patients receiving enteral nutrition
Publikováno v:
Diabetes. 70
Diabetes self-management education and support (DSMES) is known to improve diabetes treatment outcomes, but this limited resource is not always targeted toward the highest risk patients in current models of care. Predictive modeling, which relies on
Autor:
Ryan M. Farrell, Bereket Tesfaldet, Mitchell E. Geffner, Rachana Shah, Megan M. Kelsey, Jeanie B. Tryggestad, Elvira Isganaitis, Joyce Keady, Michelle A. Van Name, Steven D. Chernausek
Publikováno v:
Diabetes. 70
Background: Prenatal exposures, including parental nutrition and diabetes (DM) status, are increasingly viewed as risk factors for future cardiometabolic health. There are currently no data on effects of parental DM on disease progression or complica
Autor:
Jose C. Florez, Catherine Allard, Marie-France Hivert, Sarah Hsu, Alisa K. Manning, Camille E. Powe, Patrice Perron, Luigi Bouchard, Denise M. Scholtens, Alan Kuang, Miriam S. Udler, William Lowe
Publikováno v:
Diabetes. 69
Background: We previously described physiology-informed genetically-anchored type 2 diabetes (T2D) clusters based on associations between glycemic traits and T2D-associated variants discovered in prior GWAS. Cluster polygenic scores (PSs) delineate T
Autor:
Steven Terra, Robert Frederich, Urszula Masiukiewicz, James P. Mancuso, Silvina Gallo, Brett Lauring, Shrita M. Patel, Mary A. Hickman, Susan Huyck, Susan L. Johnson
Publikováno v:
Diabetes. 67
Ertugliflozin (ERTU) is an SGLT2 inhibitor for the treatment of T2DM. The risk of fracture was assessed in adults with T2DM receiving ERTU relative to placebo (PBO) or active comparator in pooled analyses of 7 randomized, double-blind, Phase 3 trials
Publikováno v:
Diabetes. 67
Children exposed in utero to maternal type 2 diabetes (T2D) or gestational diabetes (GDM) diagnosed by 26 weeks gestation are at increased risk of autism spectrum disorders (ASD). Here we assessed the association between ASD and in utero exposure to
Autor:
Bernard Charbonnel, Susan Huyck, Steven G. Terra, Silvina Gallo, Brett Lauring, Allison Goldman, Amanda Darekar, Harry Shi
Publikováno v:
Diabetes. 67
This Phase 3 randomized, double-blind study in adults with T2DM (A1C 7.0-10.5%) on MET monotherapy (≥1500 mg/day ≥8 weeks) included a 26 week placebo (PBO)-controlled period followed by a 78 week extension where non-rescued PBO pts with fasting f
Autor:
Sakeneh Zraika, Feng Wang, Steven E. Kahn, Kristina M. Utzschneider, Melissah R. Watts, Zhen Ping Shen, Darcy B. Carr, Keiichi Kodama, Rebecca L. Hull
Publikováno v:
Diabetes. 54:2235-2244
Islet amyloid deposition in type 2 diabetes is associated with reduced β-cell mass. Therefore, interventions aimed at reducing islet amyloid formation may help preserve β-cell mass in type 2 diabetes. Rosiglitazone and metformin act by different me
Publikováno v:
Diabetes. 38:291-303
Basal insulin supplementation has been used as a therapy for patients with non-insulin-dependent diabetes mellitus (NIDDM) who require insulin. To determine whether basal insulin supplementation in addition to lowering postabsorptive plasma glucose c
Publikováno v:
Diabetes. 30:9-13
The capacity of a fetal rat pancreas to grow and function was assessed after its transplantation into adult diabetic rats. One month after induction of diabetes by streptozotocin (SZ) (72.5 mg/kg) in adult Lewis rats, one syngeneic 17-17½ day fetal